Your browser doesn't support javascript.
Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with sotrovimab in the community in England.
Harman, Katie; Nash, Sophie Grace; Webster, Harriet H; Groves, Natalie; Hardstaff, Jo; Bridgen, Jessica; Blomquist, Paula B; Hope, Russell; Ashano, Efejiro; Myers, Richard; Rokadiya, Sakib; Hopkins, Susan; Brown, Colin S; Chand, Meera; Dabrera, Gavin; Thelwall, Simon.
  • Harman K; UKHSA COVID-19 National Epidemiology Cell, London, UK.
  • Nash SG; UKHSA COVID-19 National Epidemiology Cell, London, UK.
  • Webster HH; UKHSA COVID-19 National Epidemiology Cell, London, UK.
  • Groves N; UKHSA Genomics and Public Health Analysis, London, UK.
  • Hardstaff J; UKHSA Outbreak Surveillance Team, London, UK.
  • Bridgen J; UKHSA Outbreak Surveillance Team, London, UK.
  • Blomquist PB; UKHSA Outbreak Surveillance Team, London, UK.
  • Hope R; UKHSA COVID-19 National Epidemiology Cell, London, UK.
  • Ashano E; UKHSA HCAI, Fungal, AMR, AMU & Sepsis Division, London, UK.
  • Myers R; UKHSA Genomics and Public Health Analysis, London, UK.
  • Rokadiya S; UKHSA COVID-19 Therapeutics, London, UK.
  • Hopkins S; UKHSA Chief Medical Advisor, London, UK.
  • Brown CS; UKHSA HCAI, Fungal, AMR, AMU & Sepsis Division & NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK.
  • Chand M; UKHSA Genomics and Public Health Analysis, London, UK.
  • Dabrera G; UKHSA COVID-19 National Epidemiology Cell, London, UK.
  • Thelwall S; UKHSA COVID-19 National Epidemiology Cell, London, UK.
Influenza Other Respir Viruses ; 17(5): e13150, 2023 05.
Artículo en Inglés | MEDLINE | ID: covidwho-20236565
ABSTRACT
There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub-lineage of the Omicron SARS-CoV-2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74-1.86). These results suggest that the risk of hospital admission was similar between the two sub-lineages.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico Tópicos: Variantes Límite: Humanos País/Región como asunto: Europa Idioma: Inglés Revista: Influenza Other Respir Viruses Asunto de la revista: Virología Año: 2023 Tipo del documento: Artículo País de afiliación: Irv.13150

Similares

MEDLINE
LILACS
LIS
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico Tópicos: Variantes Límite: Humanos País/Región como asunto: Europa Idioma: Inglés Revista: Influenza Other Respir Viruses Asunto de la revista: Virología Año: 2023 Tipo del documento: Artículo País de afiliación: Irv.13150